UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Journal for immunotherapy of cancer, 2016-10, Vol.4 (1), p.60-60, Article 60

2016

Volltextzugriff (PDF)

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Annals of oncology, 2015-11, Vol.26 (11), p.2267-2274

2015

Volltextzugriff (PDF)

Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma

Annals of oncology, 2011-04, Vol.22 (4), p.787-793

2011

Volltextzugriff (PDF)

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors

Annals of oncology, 2015-07, Vol.26 (7), p.1481-1487

2015

Volltextzugriff (PDF)

Characterization of a messenger RNA polynucleotide vaccine vector

Cancer research (Chicago, Ill.), 1995-04, Vol.55 (7), p.1397-1400

1995

Volltextzugriff (PDF)

Human Autoantibodies to Carcinoembryonic Antigen (CEA) Induced by a Vaccinia-CEA Vaccine

Clinical cancer research, 2000-01, Vol.6 (1), p.34-41

2000

Volltextzugriff (PDF)

Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration

Clinical cancer research, 1999-09, Vol.5 (9), p.2330-2337

1999

Volltextzugriff (PDF)

Immune response to a carcinoembryonic antigen polynucleotide vaccine

Cancer research (Chicago, Ill.), 1994-03, Vol.54 (5), p.1164-1168

1994

Volltextzugriff (PDF)

Human immune response to monoclonal antibodies

Journal of immunotherapy with emphasis on tumor immunology, 1994-01, Vol.15 (1), p.42

1994

Volltextzugriff (PDF)

Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen

Clinical cancer research, 1998-11, Vol.4 (11), p.2903-2912

1998

Volltextzugriff (PDF)

Polynucleotide-mediated immunization therapy of cancer

Seminars in oncology, 1996-02, Vol.23 (1), p.135-147

1996

Volltextzugriff (PDF)

Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration

Journal of immunotherapy with emphasis on tumor immunology, 1995-11, Vol.18 (4), p.231

1995

Volltextzugriff (PDF)

Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials

Journal of immunotherapy, 2000-05, Vol.23 (3), p.379-386

2000

Volltextzugriff (PDF)

A carcinoembryonic antigen polynucleotide vaccine for human clinical use

Cancer gene therapy, 1995-03, Vol.2 (1), p.33

1995

Volltextzugriff (PDF)

Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients

Clinical cancer research, 2002-09, Vol.8 (9), p.2782-2787

2002

Volltextzugriff (PDF)

Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma

Clinical cancer research, 2005-06, Vol.11 (11), p.4168-4175

2005

Volltextzugriff (PDF)

A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma

Cancer biotherapy & radiopharmaceuticals, 2006-12, Vol.21 (6), p.561

2006

Volltextzugriff (PDF)

SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma

Cancer gene therapy, 2000-03, Vol.7 (3), p.446-455

2000

Volltextzugriff (PDF)

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse

Journal of immunotherapy (1997), 2005-07, Vol.28 (4), p.382

2005

Volltextzugriff (PDF)

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity

Cancer biotherapy & radiopharmaceuticals, 2006-12, Vol.21 (6), p.553

2006

Volltextzugriff (PDF)

Sorafenib for Advanced and Refractory Desmoid Tumors

The New England journal of medicine, 2018-12, Vol.379 (25), p.2417-2428

2018

Volltextzugriff (PDF)

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Clinical cancer research, 2021-10, Vol.27 (19), p.5236-5247

2021

Volltextzugriff (PDF)

E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

Clinical cancer research, 2019-01, Vol.25 (2), p.524-532

2019

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Humans
(25)
Female
(19)
Aged
(15)
Male
(15)
Middle Aged
(15)
Immunotherapy
(13)
Adult
(12)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Antineoplastic Agents
(11)
Pharmacology. Drug Treatments
(11)
Animals
(10)
Medicine, Research & Experimental
(9)
Research & Experimental Medicine
(9)
Aged, 80 And Over
(8)
Carcinoembryonic Antigen - Immunology
(8)
Mice
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors

Characterization of a messenger RNA polynucleotide vaccine vector

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Human Autoantibodies to Carcinoembryonic Antigen (CEA) Induced by a Vaccinia-CEA Vaccine

Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration

Immune response to a carcinoembryonic antigen polynucleotide vaccine

Human immune response to monoclonal antibodies

Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen

Polynucleotide-mediated immunization therapy of cancer

Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration

Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials

A carcinoembryonic antigen polynucleotide vaccine for human clinical use

Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients

Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma

A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma

SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity

Sorafenib for Advanced and Refractory Desmoid Tumors

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)

E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

Aktive Filter

Suchergebnisse filtern